Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP

Future Oncology

Volumn 11, Issue 4, 2015, Pages 617-627

  Kobayashi, Yoshimitsu ^a   Komatsu, Yoshito ^b   Yuki, Satoshi ^a   Fukushima, Hiraku ^b   Sasaki, Takahide ^a   Iwanaga, Ichiro ^c   Uebayashi, Minoru ^c   Okuda, Hiroyuki ^d   Kusumi, Takaya ^d   Miyagishima, Takuto ^e   Sogabe, Susumu ^e   Tateyama, Miki ^f   Hatanaka, Kazuteru ^g   Tsuji, Yasushi ^h   Nakamura, Michio ⁱ   Konno, Jun ^j   Yamamoto, Fumiyasu ^k   Onodera, Manabu ^l   Iwai, Kazuhiro ^m   Sakata, Yuh ⁿ   Abe, Riichiro ^a   Oba, Koji ^b   Sakamoto, Naoya ^a   more..

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c Japanese Red Cross Kitami Hospital   (Japan)

^d Keiyukai Sapporo Hospital   (Japan)

^e KUSHIRO ROSAI HOSPITAL   (Japan)

^f Tomakomai Nisshou Hospital   (Japan)

^g Hakodate Municipal Hospital   (Japan)

^h Tonan Hospital   (Japan)

ⁱ SAPPORO CITY GENERAL HOSPITAL   (Japan)

^j HAKODATE CENTRAL GENERAL HOSPITAL   (Japan)

^k Tomakomai City Hospital   (Japan)

^l Abashiri Kosei General Hospital   (Japan)

^m Division of Anesthesia Oji General Hospital   (Japan)

ⁿ Misawa City Hospital   (Japan)

more..

Author keywords

colorectal cancer; Japanese; panitumumab; pre emptive; skin toxicities

Indexed keywords

FLUOROURACIL; FOLINIC ACID; HYDROCORTISONE; IRINOTECAN; MINOCYCLINE; PANITUMUMAB; SUNSCREEN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ACNE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFECT; DRY SKIN; FATIGUE; FEMALE; HUMAN; HYPOMAGNESEMIA; INCIDENCE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PARONYCHIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPLICATION; JAPAN; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN DISEASES; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN DISEASES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923094904     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.251     Document Type: Article

References (30)

1. Foon KA, Yang XD, Weiner LM et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 58, 984-990 (2004).
2. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236-1243 (1999).
3. Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25, 1658-1664 (2007).
4. Peeters M, Price TJ, Cervantes A et al Randomized Phase III study of panitumumab with fuorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 4706-4713 (2010).
5. Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fuorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as frst-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28, 4697-4705 (2010).
6. Peeters M, Balfour J, Arnold D. Review article: panitumumab-a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Aliment. Pharmacol. Ther. 28, 269-281 (2008).
7. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 6, 803-812 (2006).
8. Bouché O, Beretta GD, Alfonso PG, Geissler M. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treat. Rev. 36(Suppl. 1), S1-S10 (2010).
9. Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr. Oncol. 17(Suppl. 1), S18-S30 (2010).
10. Naughton MJ, Schrag D, Venook AP et al. Quality of life (QOL) and toxicity among patients in CALGB 80405. J. Clin. Oncol. 31(Suppl.), Abstract 3611 (2013).
11. Van Cutsem E. Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer. Clin. Colorectal Cancer 6 (Suppl. 2), S60-S65 (2007).
12. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
13. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. 23, 5235-5246 (2005).
14. Stintzing S, Kapaun C, Laubender RP et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int. J. Cancer 132, 236-245 (2013).
15. Duvic M. EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am. J. Clin. Dermatol. 9, 285-294 (2008).
16. Segaert S, Tabernero J, Chosidow O et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J. Dtsch. Dermatol. Ges. 3, 599-606 (2005).
17. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72, 152-159 (2007).
18. Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann. Phar macother. 43, 1658-1666 (2009).
19. Lacouture ME, Mitchell EP, Piperdi B et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a Phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 1351-1357 (2010).
20. UMIN Clinical Trials Registry (UMIN-CTR). https://upload.umin.ac.jp
21. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210-216 (1994).
22. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000).
23. Bianchini D, Jayanth A, Chua YJ, Cunningham D. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. Clin. Colorectal Cancer 7, 33-43 (2008).
24. Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 77, 120-123 (2009).
25. Lai SE, Minnelly L, O'Keeffe P et al. Infuence of skin color in the development of erlotinib-induced rash: a report from the SERIES clinic. J. Clin. Oncol. 25(Suppl.), Abstract 9127 (2007).
26. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and effcacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large Phase III studies. Clin. Cancer Res. 13, 3913-3921 (2007).
27. Kubota K, Nishiwaki Y, Tamura T et al. Effcacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small-cell lung cancer: a Phase II study. J. Thorac. Oncol. 3, 1439-1445 (2008).
28. Macdonald A. Topical corticosteroid preparations. Hazards and side-effects. Br. J. Clin. Pract. 25, 421-425 (1971).
29. Purdy MJ. Adverse effects of strong topical corticosteroids. Drugs 8, 70-77 (1974).
30. Scope A, Agero AL, Dusza SW et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J. Clin. Oncol. 25, 5390-5396 (2007).